The European Medicines Agency (EMA), the EU's drug regulator, has approved the use of Pfizer (NYSE:PFE)-BioNTech's (Nasdaq:BNTX) COVID-19 vaccine for children between the ages of five and 11, Reuters news agency reported on Thursday.
The EMA has recommended that the vaccine, which is called Comirnaty, will be given in two doses of 10 micrograms three weeks apart as an injection in the upper arm. Adult doses contain 30 micrograms.
The EMA said: "The benefits of Comirnaty in children aged five to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19."
According to the companies, their vaccine showed 90.7% efficacy against COVID-19 in a clinical trial of children aged five to 11.
While final approval is up to the European Commission, it typically follows EMA recommendations.
Tens of millions of children in this age group will be eligible for the shot in the EU, Reuters noted.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval